title: Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
authors.forename: José María
authors.initials: JM
authors.lastname: Martínez-Ortega
authors.forename: Francisco
authors.initials: F
authors.lastname: Diaz-Atienza
authors.forename: Luis
authors.initials: L
authors.lastname: Gutiérrez-Rojas
authors.forename: Dolores
authors.initials: D
authors.lastname: Jurado
authors.forename: Manuel
authors.initials: M
authors.lastname: Gurpegui
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000009:adverse effects*; D000068180:Aripiprazole; D019958:Attention Deficit and Disruptive Behavior Disorders / Q000188:drug therapy; D001569:Benzodiazepines / Q000009:adverse effects; D001714:Bipolar Disorder / Q000188:drug therapy; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D002648:Child; D003987:Dibenzothiazepines / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D000077152:Olanzapine; D010879:Piperazines / Q000009:adverse effects; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000009:adverse effects; D018967:Risperidone / Q000009:adverse effects; D012559:Schizophrenia / Q000188:drug therapy; D013030:Spain; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D000068180:Aripiprazole; D018967:Risperidone; D000077152:Olanzapine